GLYZIMAC TOTAL 30 TABLET - Gliclazide 30mg+pioglitazone 15mg+metformin Hydrocloride 500mg

Product Description

GLYZIMAC TOTAL 30 TABLET is a powerful triple-action oral antidiabetic formulation combining Gliclazide, Pioglitazone, and Metformin. Designed to offer comprehensive glycemic control in patients with Type 2 Diabetes Mellitus, this tablet improves insulin sensitivity, enhances glucose uptake, and regulates blood sugar effectively.

Manufactured under WHO-GMP certified conditions, GLYZIMAC TOTAL 30 is trusted by healthcare professionals for its synergistic mechanism and high patient compliance. It is ideal for bulk pharmaceutical buyers, diabetology clinics, hospital supply chains, and retail pharmacy distributors.

Key Benefits:

• Triple-drug combination for better glycemic regulation

• Gliclazide stimulates insulin secretion

• Pioglitazone improves insulin sensitivity

• Metformin reduces hepatic glucose production

• Reduces the need for multiple medications with once-daily convenience

Applications:

• Effective for the management of Type 2 Diabetes Mellitus

• Supports long-term blood sugar control in adults

• Recommended in combination therapy for insulin-resistant patients

Why Choose GLYZIMAC TOTAL 30 TABLET?

• High-demand diabetic care product with consistent market performance

• Ideal for pharmaceutical wholesalers and hospital tenders

• Strong profit margins and ready availability for B2B partners